Marcel Nijland

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

Jacoline E. C. Bromberg, Samar Issa, Katerina Bakunina et al. · The Lancet Oncology · 2019 · 235 citations

Medicine, Oncology, Pharmacotherapy +10

HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?

Marcel Nijland, Rianne Veenstra, Lydia Visser et al. · OncoImmunology · 2017 · 116 citations · Full text

Life Sciences, Hematology, Immunology +17

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

Marie José Kersten, Julia Driessen, Josée M. Zijlstra et al. · Haematologica · 2020 · 102 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

<i>MYD88</i> mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis

Joost S.P. Vermaat, Sebastiaan Somers, Liesbeth C. de Wreede et al. · Haematologica · 2019 · 90 citations · Full text

Medicine, Oncology, Pathology +17

Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)

Pieternella J. Lugtenburg, Peter de Nully Brown, Bronno van der Holt et al. · Journal of Clinical Oncology · 2020 · 86 citations · Full text

Medicine, Oncology, Pharmacotherapy +7